Core One Labs To Patent Biosynthesised Psilocybin For Medical Psychedelic Market

2 Mins Read

Core One Labs, the Canadian startup bringing psychedelic medicines to market, says it is days away from finishing its U.S. patent application for its subsidiary company Vocan’s biosynthetic psilocybin production system. Vocan’s proprietary production method is cost-effective, enabling what the company has described as an “innovative and first-to-market delivery method” of psilocybin—magic mushrooms—in medical treatments for depression, anxiety, and addiction.

Vancouver-based Core One Labs has announced that it is now in the final stages of completing its U.S. patent application for its proprietary biosynthetic psilocybin production after four months of “great strides” in further development of Vocan’s system. Vocan has been working with researchers at the University of British Columbia (UBC) to develop its novel production method for psilocybin, also known as magic mushrooms. 

Bringing Psilocybin to Market

Unlike current psilocybin production methods and synthetic processing techniques, Vocan’s biosynthesised psilocybin production removes the cost prohibitions associated with bringing psilocybin to the medical market, and can consistently produce the same quality and concentration that stereochemically rivals its naturally-occurring compound. 

Joel Shacker, CEO of Core One Labs, said: “Core One Labs submitting its patent for its revolutionary biosynthetic psilocybin production system is imminent as we are just days away. This could position the Company as the leader in provision of pharmaceutical API grade psilocybin.” 

Core One says it believes that as interest in the therapeutic and medical benefits of psilocybin continues to grow, its cost-effective biosynthetic production will also hold “wide appeal” for further research into psychedelics medicines and clinical industries globally. 

Read: Are psychedelics making a wellness and health comeback?

“We have assembled a world class team to promote and sell our biosynthesised psilocybin to other major companies that are working on therapeutic psychedelic solutions. With current prices of psilocybin being over $7000 USD per gram, we view this space as being highly profitable,” explained Shacker. 

Mental Health Treatment

Core One plans to use the biosynthesised psilocybin in conjunction with its patented transmucosal thinstrip delivery method, which allows for more accurate dosing for people who use psychedelic treatment methods for mental health conditions such as anxiety, depression and addiction. 

The thinstrip technology that the company has developed is non-toxic, biodegradable and can reduce the symptoms of inaccurate dosing, which include hallucinations and digestive issues, because it skips the digestive system and allows patients to absorb the substance directly into the bloodstream. 

“Direct delivery to the bloodstream means that dosages can be less potent with the same effect,” said the company in a press statement. 

Attention on the use of natural occurring compounds such as CBD, THC and psilocybin have risen in popularity in recent years as more scientific evidence comes to light about the effectiveness of natural alternative treatments. 

In particular with psilocybin, a recent study published in the New England Journal of Medicine that compared the use of psilocybin and the established antidepressant drug escitalopram among a selected group of patients found no significant difference in effects between the two.


Lead image courtesy of Pixabay. 

mushrooms